Moreover, as outlined by literature previously, EP2 receptor antagonists and PGD2 inhibitors prove to be interesting potential therapeutics for the treatment of MS due to their inflammatory nature within MS murine models. The gene discussed is HPGDS; the disease is myeloid sarcoma.